

Contains Nonbinding Recommendations

Draft Guidance on Tinidazole

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Tinidazole

Form/Route: Tablet/Oral

Recommended studies: 1 study

Type of study: Fed

Design: Single-dose, two-treatment, two-period crossover *in-vivo*

Strength: 500 mg

Subjects: Normal healthy males and females, general population.

Additional comments:

Analytes to measure (in appropriate biological fluid): Tinidazole in plasma

Bioequivalence based on (90% CI): Tinidazole

Waiver request of in-vivo testing: 250 mg based on (i) acceptable bioequivalence studies of the 40 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution testing to document bioequivalence:

Apparatus: USP Apparatus 1 (basket)

Rotation speed: 100 rpm

Medium: 0.1N HCl (or 0.1N HCl with NaCl) at pH 1.2, pH 4.5 acetate buffer, pH 6.8 phosphate buffer, and water

Volume: 900 mL

Temperature: 37°C

Sample times: 5, 10, 15, 20, 25, 30, and 40 min or as needed for profile comparisons

Additional comments: All raw data (test and reference products) should be submitted with means at each sampling point, the range (minimum and maximum values), the percentage of coefficient of variation (%CV), and f2 value tabulated (if appropriate). The dissolution testing should be conducted on 12 units from the same lot numbers that are used in the in vivo bioequivalence study.

Dissolution testing for stability and quality control:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.